Mark Bamberger

Mark Bamberger

Company: Stealth BioTherapeutics

Job title: Chief Scientific Officer


Mark Bamberger is the Chief Scientific Officer of Stealth BioTherapeutics. As a former Director of Cardiovascular and Metabolic Disease Research at Pfizer, he has more than 20 years of diverse scientific and executive experience in both drug discovery and early clinical development. Mark was responsible for the initiation of multiple drug discovery programs and the advancement of multiple compounds into clinical development. Mark received his PhD in Biochemistry from the Medical College of Pennsylvania followed by a postdoctoral fellowship in the Dept. of Biological Chemistry Johns Hopkins University School of Medicine.


Mitochondrial Dysfunction & Aging: Elamipretide as a Potential Intervention 2:30 pm

Understanding how mitochondrial dysfunction is complicit in multiple age-related diseases Demonstrating the potential to impact aging by improving mitochondrial function in preclinical studies Introducing Elamipretide, a novel, first in class mitochondrial therapeutic in clinical development Exploring how multiple preclinical studies support elamipretide as a potential therapy for age-related diseasesRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.